Summary: Resurrect Bio has announced the initial close of its Series A financing round, securing over $8 million to advance its mission of becoming the world’s leading plant disease resistance company. The round, led by Corteva Agriscience, will fund the acceleration of in-house crop protection traits and the advancement of FloraFold® AI, the company’s proprietary computational protein-protein interaction screening tool.
Resurrect Bio Secures Over $8 Million in Series A Led by Corteva Agriscience
March 2026
Resurrect Bio has made an initial close of over $8 million in its Series A financing round, marking a significant milestone in its mission to become the world’s leading plant disease resistance company.
The round was led by Corteva Agriscience, alongside a strong syndicate of investors including Calculus Capital, Pymwymic, UK Innovation & Science Seed Fund [UKI2S], SynBioVen, and AgFunder. Through this partnership, the team is focused on strengthening global food security and providing viable, sustainable alternatives to chemical inputs.
- FloraFold® AI: The financing will take the company’s advanced computational protein-protein interaction screening tool to the next level.
- Crop Protection Traits: Capital will be deployed to ramp up the production of Resurrect Bio’s in-house crop protection traits.
- Global Impact: Advancing technologies designed to bolster global food security by increasing inherent plant disease resistance.
“We are on a mission to become the world’s leading plant disease resistance company and this investment brings us one step closer,” the company stated in its announcement, extending its gratitude to all investors, advisors, mentors, partners, and its internal team throughout the process.
Leave a Reply